lx2020
·Code: LX2020
lx2020: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Study of the Safety and Efficacy of LX2020 Gene Therapy in Patients With Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant
Frequently asked questions
Who is developing lx2020?
lx2020 is being developed by Lexeo Therapeutics, Inc..
How many clinical trials involve lx2020?
BioSniper tracks 1 clinical trial involving lx2020.
Get deeper analysis on lx2020
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis